Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
-
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
-
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
-
Aptose Reports Second Quarter 2025 Results
-
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
-
Aptose has received an additional advance of US$2.0M from Hanmi Pharmaceutical Co. as part of a US$8.5M loan facility agreement.
-
Aptose Upgraded to Trade on OTCQB Market
-
Aptose Announces Deferral of Interest Payment
-
Aptose and Hanmi Pharmaceutical Enter New Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
-
Aptose announces corporate updates